Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431564 | 0.83 | ATM (0.59) | CYP11B1CYP11B2CYP3A4ALDH1A1 | |
| SCHEMBL21251416 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL22474091 | 0.79 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL7877554 | 0.79 | SRD5A2 (0.89) | SRD5A2MEN1LMNAKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL26136027 | 0.78 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL68390 | 0.76 | SRD5A2 (0.69) | SRD5A2LMNAKMT2AALDH1A1RXRA | |
| SCHEMBL19540958 | 0.75 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL16880980 | 0.75 | HCAR2 (0.49) | SRD5A2HCAR2CYP11B1CYP11B2MEN1 | |
| SCHEMBL24088663 | 0.75 | RXRA (0.65) | HCAR2ALDH1A1RXRARXRBSMN1; SMN2 | |
| SCHEMBL9318665 | 0.75 | MEN1 (0.52) | SRD5A2HCAR2CYP11B1CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1798729-A | Benzamide nitrile derivatives | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
| EP-1633701-A1 | BENZAMIDE NITRILE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106285-A1 | BENZAMIDE NITRILE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248949-A1 | Benzamide nitriles | ROCHE PALO ALTO LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2000048993-A1 | ARYLAMINOALKYLAMIDES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248949-A1 | Benzamide nitriles | CTSK, CTSS, CMA1 | SRD5A2 2667/4885HCAR2 2178/4885CYP11B1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.